ConvaTec Regulatory News (CTEC)

30 November 2022

Convatec Group Plc
("Convatec" or "the Company")

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 November 2022, the Company's issued capital with voting rights consisted of 2,043,872,048 ordinary shares of 10p each (‘Shares’). The Company does not hold any Shares in Treasury at the date of this disclosure.

The above figure (2,043,872,048) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the UK Financial Conduct Authority's Disclosure and Transparency Rules. 

Enquiries 

Analysts and Investors 

Kate Postans, VP Investor Relations, Convatec                                                            +44 (0)782 644 7807 

ir@convatec.com 

About Convatec 
 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. With around 10,000 colleagues, and a promise to be forever caring, our products and services are available in over 100 countries. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. The company is a constituent of the FTSE 100 Index (LSE:CTEC) and in 2021 revenues were over $2 billion. To learn more about Convatec, please visit http://www.convatecgroup.com